Aquatic Capital Management LLC Acquires New Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Aquatic Capital Management LLC bought a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 57,610 shares of the company's stock, valued at approximately $456,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at $81,000. Straightline Group LLC acquired a new position in Amneal Pharmaceuticals in the 4th quarter worth about $92,000. Cibc World Markets Corp acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $118,000. Janney Montgomery Scott LLC purchased a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at approximately $121,000. Finally, Fox Run Management L.L.C. raised its position in Amneal Pharmaceuticals by 69.0% during the fourth quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock worth $162,000 after acquiring an additional 8,342 shares during the period. 31.82% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMRX has been the subject of several recent analyst reports. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Barclays raised their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, March 3rd. Finally, StockNews.com upgraded Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $11.50.

Amneal Pharmaceuticals Price Performance

NASDAQ:AMRX traded up $0.33 during mid-day trading on Thursday, reaching $7.55. The company's stock had a trading volume of 648,556 shares, compared to its average volume of 1,725,749. The stock has a market cap of $2.34 billion, a P/E ratio of -11.10 and a beta of 1.17. The company's fifty day simple moving average is $7.95 and its two-hundred day simple moving average is $8.14. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.29 and a twelve month high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Friday, May 2nd. The company reported $0.19 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.05. The business had revenue of $695.42 million during the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. Sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gautam Patel sold 80,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the sale, the director now owns 1,808,886 shares in the company, valued at approximately $16,099,085.40. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 26.56% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.